Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 911

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 911
---
  511 | ​ | ​ |

As of December 31, 2023, the expected remaining amortization expense is as follows (in thousands):

| Year Ended December 31, 
 2024                    | ​ 
 ​ | ​ 
 ​ | Amount 
 ​      |   |  63 | ​ | ​ 
 ​ |
|:------------------------|:--|:--|:-------|:--|----:|:--|:--|
| 2025                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2026                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2027                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| 2028                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| Thereafter              | ​ | ​ | ​      | ​ | 133 | ​ | ​ |
| Total                   | ​ | ​ | ​      | $ | 448 | ​ | ​ |

The Company recognized less than $0.1 million for amortization expense for each of the years ended December 31, 2023 and 2022, respectively. Amortization expense is included in research and development expense in the statements of operations and comprehensive loss. 6. Accrued Expenses Accrued expenses consisted of the following as of December 31, 2023 and 2022 (in thousands):

| ​                                          
 ​                                          | ​ 
 ​ | ​ 
 ​ | As of December 31, 
 2023               |   |       |   | ​ | ​ | 2022 |   |       |   | ​ 
 ​ |
|:-------------------------------------------|:--|:--|:-------------------|:--|------:|:--|:--|:--|:-----|:--|------:|:--|:--|
| Accrued research and development expenses  | ​ | ​ | ​                  | $ |   574 | ​ | ​ | ​ | ​    | $ |   899 | ​ | ​ |
| Accrued employee compensation and benefits | ​ | ​ | ​                  | ​ |   942 | ​ | ​ | ​ | ​    | ​ |   678 | ​ | ​ |
| Other accrued expenses                     | ​ | ​ | ​                  | ​ |    61 |